Skip to main
NTRA
NTRA logo

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 35%
Buy 62%
Hold 4%
Sell 0%
Strong Sell 0%

Bulls say

Natera Inc's strong financial outlook is supported by significant gross margin expansion, which has improved from the low 40s to approximately 60%, driven by the successful mix of higher-priced tests like Signatera and expanded payor reimbursements. The company has demonstrated robust revenue growth, increasing nearly six-fold since 2019, positioning itself favorably within the $30 billion cancer screening total addressable market (TAM) alongside its dominance in non-invasive prenatal testing (NIPT) and minimal residual disease (MRD) testing. Furthermore, the anticipated growth in Medicare Advantage reimbursement rates for Signatera, projected to reach the mid-to-high 60% range by the end of 2024, underscores Natera's potential for continued revenue growth and enhanced market coverage.

Bears say

Natera Inc faces significant risk to its revenue streams and overall path to profitability due to potential reductions in reimbursement from payors for its diagnostic products and services. Additionally, ongoing compression of average selling prices (ASP) for products like Panorama is likely to further erode margins, raising concerns about sustainable profitability. Finally, potential delays in clinical trial results and logistical challenges could hinder the company's long-term revenue growth projections, contributing to a negative outlook on its financial stability.

Natera (NTRA) has been analyzed by 26 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 62% recommend Buy, 4% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 26 analysts, Natera (NTRA) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $155.31, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $155.31, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.